In a recent study, researchers found that most users regain two-thirds of the weight they lost within 6 to 12 months after stopping the drug
While GLP-1 receptor agonists (such as semaglutide and liraglutide) have demonstrated significant benefits in diabetes management, weight reduction, and cardiovascular outcomes in clinical trials, enhancing physiological GLP-1 through dietary and lifestyle modifications represents a foundational approach
[4] [5] For weight management, NICE technology appraisals (TA875 for Wegovy, TA664 for Saxenda) specify these treatments should be used within specialist weight management services (tier 3 or 4), with specific eligibility criteria, time-limited use, and defined stopping rules
Second Nature is an all-in-one service: it prescribes Mounjaro or Wegovy, delivers the medication, and provides dietitian-led coaching alongside a structured behaviour change programme
More real-world comparisons are needed to determine whether this would be more effective than semaglutide, said Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA
Thirdly, GLP-1 agonists slow gastric emptying, leading to a delayed absorption of nutrients and a prolonged feeling of fullness, which can contribute to reduced food intake and weight loss